MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ADVM had -$16,358K decrease in cash & cash equivalents over the period. -$28,257K in free cash flow.

Cash Flow Overview

Change in Cash
-$16,358K
Free Cash flow
-$28,257K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-47,652 -96,210
Depreciation and amortization
465 1,218
Stock-based compensation expense
2,349 5,201
Net accretion of discount on marketable securities
16 528
Non-cash lease expense
83 82
Non-cash sublease loss
0 982
Loss on disposal of property and equipment
-8 -
Other
-1 -12
Prepaid expenses and other current assets
-1,135 -1,568
Deposit and other long-term assets
551 125
Accounts payable
7,739 3,103
Accrued expenses and other liabilities
7,190 3,625
Lease liability
1,134 -466
Net cash used in operating activities
-28,115 -81,538
Purchases of marketable securities
0 1,976
Maturities of marketable securities
2,000 65,500
Purchases of property and equipment
142 340
Net cash provided by (used in) investing activities
1,858 63,184
Proceeds from issuance of common stock and pre-funded warrants in private placements, net of issuance costs
9,899 0
Proceeds from issuance of common stock pursuant to option exercises
0 0
Proceeds from employee stock purchase plan
0 120
Net cash provided by financing activities
9,899 120
Net (decrease) increase in cash and cash equivalents and restricted cash
-16,358 -18,234
Cash and cash equivalents at beginning of period
62,628 -
Cash and cash equivalents at end of period
28,036 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Adverum Biotechnologies, Inc. (ADVM)

Adverum Biotechnologies, Inc. (ADVM)